Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

600196 Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Closed 05-21 15:00:00

23.71

-0.31

-1.29%

High24.38	Low23.68	Vol19.60M
Open24.06	D1 Closing24.02	Amplitude2.91%
Mkt Cap63.31B	Tradable Cap50.22B	Total Shares2.67B
T/O472.00M	T/O Rate0.93%	Tradable Shares2.12B
P/B1.29	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.","latestPrice":23.71,"timestamp":1779346801000,"preClose":24.02,"halted":0,"volume":19603379,"delay":0,"changeRate":-0.0129,"floatShares":2118000000,"shares":2670000000,"eps":1.3019,"marketStatus":"Closed","change":-0.31,"latestTime":"05-21 15:00:00","open":24.06,"high":24.38,"low":23.68,"amount":472000000,"amplitude":0.0291,"askPrice":23.72,"askSize":22,"bidPrice":23.71,"bidSize":438,"shortable":0,"etf":0,"ttmEps":1.3019,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.02,"symbolType":"stock","openAndCloseTimeList":[[1779327000000,1779334200000],[1779339600000,1779346800000]],"highLimit":26.42,"lowLimit":21.62,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.29,"roa":"--","peRate":18.211844,"roe":"1.78%","epsLYR":1.27,"committee":0.806491,"marketValue":63316000000,"turnoverRate":0.0093,"status":1,"hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"FOSUN PHARMA","latestPrice":17.48,"timestamp":1779350895004,"preClose":17.66,"halted":0,"volume":1955575,"delay":0,"premium":"-36.02"},"floatMarketCap":50229000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2637385819","title":"Sinopharm Group  Stock Sheds 1.2% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2637385819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637385819?lang=en_us&edition=fundamental","pubTime":"2026-05-21 16:33","pubTimestamp":1779352380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slid 1.2% to 17.52 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.0% to 25386.52.The stock's fall snapped a two-day winning streak.Sinopharm Group Co. Ltd. closed 22% short of its 52-week high of HK$22.34, which the company achieved Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.0%.Trading volume totaled 7.2 million shares, compared to the 50-day average of 5.7 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK0175","02196","BK0188","BK0096","BK0239","LU1115378108.SGD","BK1197","BK1191","BK1500","BK0183","BK0028","LU0640798160.USD","BK0196","BK0012","600196","BK4175","01099","BK1515","SHTDY","BK0060","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636253630","title":"Sinopharm Group  Stock Falls 2.1% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2636253630","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636253630?lang=en_us&edition=fundamental","pubTime":"2026-05-18 16:33","pubTimestamp":1779093180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. slipped 2.1% to 17.51 Hong Kong dollars on what proved to be an all-around rough trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.1% to 25675.18.This was the stock's fourth consecutive day of losses.Sinopharm Group Co. Ltd. closed 22% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 1.8%.Trading volume totaled 5.7 million shares, compared to the 50-day average of 5.7 million shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1500","01099","BK0187","600196","LU0640798160.USD","BK0060","BK1197","BK0188","BK1593","BK4175","LU1115378108.SGD","SHTDY","02196","BK0183","BK0028","BK0012","BK0196","BK1191","BK0239","BK1515","BK0175","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123897620","title":"FOSUN PHARMA's Strategic Move: $60 Million Secures Potential Over $2.5 Billion for AR1001","url":"https://stock-news.laohu8.com/highlight/detail?id=1123897620","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123897620?lang=en_us&edition=fundamental","pubTime":"2026-05-14 17:49","pubTimestamp":1778752148,"startTime":"0","endTime":"0","summary":"On May 13th, an agreement between FOSUN PHARMA (600196; 02196) and South Korea's AriBio sent significant ripples through China's pharmaceutical investment community. This is not merely a transaction...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0239","BK1515","BK1593","BK0196","BK0187","600196","BK0028","02196","BK0188","BK0175","BK0060","BK0183","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635645367","title":"Fosun Pharma Secures $60 Million Option for Alzheimer's Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2635645367","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635645367?lang=en_us&edition=fundamental","pubTime":"2026-05-14 12:37","pubTimestamp":1778733478,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  subsidiary Fosun Pharma Industrial signed an exclusive option agreement with South Korea's AriBio for AR1001, an oral drug candidate for early Alzheimer's disease.The unit will pay a $60 million option fee and can exercise the license within 90 days after receiving topline data from an ongoing global Phase III trial.If exercised, Fosun Pharma Industrial will pay up to $180 million in upfront and regulatory milestones, plus tiered royalties.Shares of Shanghai Fosun Pharmaceutical were down 1% in recent trade on the Shanghai and Hong Kong bourses.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","BK0183","BK0028","BK0175","BK0239","600196","BK0012","BK1515","BK1593","02196","BK0196","BK0187","BK0060","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635752291","title":"Fosun Pharma and Aribio Sign Exclusive Global Option Agreement for Ar1001 for the Treatment of Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2635752291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635752291?lang=en_us&edition=fundamental","pubTime":"2026-05-14 08:00","pubTimestamp":1778716800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUAB9QT14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0096","BK0183","BK0188","600196","BK0012","BK0175","BK0060","BK0028","BK0196","BK0239","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148828379","title":"China's AI Power Consumption Set to Soar, Spotlight on Computing-Power Synergy","url":"https://stock-news.laohu8.com/highlight/detail?id=1148828379","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148828379?lang=en_us&edition=fundamental","pubTime":"2026-05-14 07:33","pubTimestamp":1778715233,"startTime":"0","endTime":"0","summary":"【Top Story】China's AI Power Consumption Set to Soar, Spotlight on Computing-Power Synergy With the official implementation of the \"Action Plan for Promoting Mutual Empowerment of Artificial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1102505929.USD","LU1323998911.USD","LU0188438112.USD","LU1224709979.USD","LU0096374516.USD","IE00B5MMRT66.SGD","IE0034224299.USD","IE0003895053.USD","HK0000352291.HKD","IE0008369823.USD","LU0181495838.USD","LU2237443382.USD","NWSGY","IE00B031HW06.USD","LU0054237671.USD","LU0417516902.SGD","LU1769817179.HKD","LU0326948709.USD","002352","LU0061477393.USD","LU0873338254.USD","IE00BGV7N243.SGD","LU2242644610.SGD","LU0320764755.SGD","LU1044876610.USD","LU0791590937.USD","LU0488056044.USD","LU0441854154.USD","LU0384037296.USD","BK1589","LU0149721374.USD","LU1868838027.USD","BK1591","LU0449509016.USD","LU1226287792.SGD","LU0244354667.USD","LU1956131251.USD","LU0211331839.USD","LU2051468812.USD","SG9999006514.SGD","HK0000320264.USD","LU0011963245.USD","LU1642822792.SGD","LU0084288322.USD","LU0791591158.USD","SG9999014898.SGD","LU0642271901.SGD","LU0516422952.EUR","LU0314109678.HKD","SG9999000327.SGD","LU0067412154.USD","BK1557","LU1691799644.USD","LU0588545490.SGD","LU1974910355.USD","LU1282651048.USD","LU0163747925.USD","IE00B8L5B284.USD","SG9999001051.SGD","LU1282651121.HKD","LU0072913022.USD","LU2237443895.HKD","SG9999001903.USD","LU0890818403.SGD","IE00BPRC5H50.USD","LU1868837722.USD","LU0127658192.USD","LU1770036033.HKD","BK1516","LU0455707207.USD","IE0032431581.USD","LU0080751232.USD","HK0000914660.USD","LU2097828557.USD","SG9999013353.USD","LU0972618739.USD","LU0823040885.USD","LU2449936058.SGD","LU0359202008.SGD","LU0823413587.USD","SG9999014914.USD","LU2476274308.USD","IE00BF5LJ272.USD","LU0210533765.USD","BK1517","LU0072462343.USD","SG9999001069.SGD","GOOGL","LU0651946864.USD","LU2177674079.SGD","LU1226288097.SGD","LU1008478684.HKD","IE00BZ08YR35.GBP","LU2097828714.EUR","GB00BDT5M118.USD","LU0501845795.SGD","LU0868486357.SGD","LU0228659784.USD","LU0878005551.USD","BK1114","IE0031814852.USD","LU0327786744.USD","LU0192582467.USD","LU1733274473.HKD","LU0543330483.HKD","BABA","LU0588545904.SGD","BK1618","BK1609","LU0049112450.USD","LU0594300179.USD","SGXZ51526630.SGD","LU1675838814.USD","LU0898667661.SGD","LU0043850808.USD","LU0348827113.USD","LU3063872942.SGD","LU0348825331.USD","LU0823426308.USD","LU1051768304.USD","LU0293314216.USD","LU1951186391.HKD","SG9999001689.USD","LU0128522157.USD","BK1502","LU1629966141.USD","LU1734074674.USD","LU2362541513.USD","LU1023057109.AUD","LU0985320562.USD","LU1868837565.USD","LU0823413660.USD","09988","LU1769817096.USD","IE00B97KM107.HKD","LU0593848301.USD","LU2226246903.HKD","LU0049853897.USD","LU0594300419.USD","LU0918141705.HKD","LU0880133367.SGD","LU2008162690.USD","LU1328277881.USD","LU1064130708.USD","LU0048388663.USD","LU2476274720.SGD","LU0203345920.USD","LU0708995153.HKD","LU0683595622.HKD","IE00B29SXG58.USD","LU0054450605.USD","LU0047713382.USD","LU0823041008.USD","LU0572944931.SGD","LU0882747503.HKD","LU0370786039.SGD","LU0611395673.USD","IE00BZ08YS42.EUR","LU0737861772.HKD","IE00BQXX3F31.USD","HK0000914686.HKD","SG9999002562.SGD","BK1608","LU0048597586.USD","LU0499858438.USD","LU0589944569.HKD","LU1688375341.USD","LU1242518931.SGD","06936","LU0328353924.USD","IE0001KFT4U8.USD","03813","LU0417516571.SGD","LU0329678337.USD","LU0784639295.USD","LU1316542783.SGD","LU0648948544.HKD","LU2257852520.SGD","LU0039217434.USD","IE00B543WZ88.USD","LU0228367735.SGD","LU0348783233.USD","LU2097828474.EUR","LU0289960550.SGD","LU0326950275.SGD","LU0456846285.SGD","LU0856984785.SGD","LU0173614495.USD","LU1831875114.USD","LU0700851271.USD","IE00BQXX3C00.GBP","LU1226287875.USD","LU0823397103.USD","SG9999014674.SGD","LU1785774172.SGD","LU1282649067.USD","LU1048596156.SGD","BK4585","LU0823397285.USD","LU2251237488.HKD","BK1610","LU1568876335.HKD","LU0051755006.USD","LU0819121731.USD","LU1481107354.HKD","SG9999001226.SGD","LU0786609619.USD","LU0577902538.SGD","HK0000151867.HKD","LU1366334651.USD","LU0633140727.USD","LU1515016050.SGD","BK4588","LU1282649810.SGD","LU0431992006.USD","LU0541502299.USD","00659","LU1725190679.HKD","SG9999007991.SGD","LU1152091754.HKD","LU0143863784.USD","HK0001040168.HKD","LU1807302812.USD","LU2293587155.HKD","LU0979878070.USD","LU1224444064.USD","00700","LU0831103253.SGD","LU0828237940.HKD","LU1242518857.USD","LU1105468828.SGD","LU1810669033.SGD","BK1095","LU0235996351.USD","IE00B031J352.USD","LU0577902454.USD","600196","SG9999015945.SGD","LU0229945570.USD","LU0509642566.USD","SG9999001846.SGD","LU0164880469.USD","03700","IE00BZ08YT58.USD","LU2498475776.HKD","LU0738912210.USD","LU1048588211.SGD","BK1526","LU0348735423.USD","IE0003795394.USD","LU0819123356.HKD","LU0541501648.USD","IE0003851619.USD","SG9999015978.USD","SG9999017495.SGD","IE0009570106.USD","LU0149534421.HKD","LU2106854487.HKD","LU2237443549.SGD","LU1226288253.USD","LU0502904849.HKD","LU1794554557.SGD","LU0128522744.USD","LU0345769128.USD","LU0414403682.SGD","LU0865486749.SGD","SG9999006597.SGD","LU0871576103.HKD","LU0264606111.USD","LU1733274390.USD","LU0143863198.USD","LU0106252389.USD","LU1960683339.HKD","LU2279701549.SGD","HK0000306701.USD","SG9999014906.USD","LU0862451837.USD","LU0588545730.USD","HTCD.SI","LU1883866441.USD","01070","LU2097828631.EUR","SG9999018857.SGD","LU1152091168.USD","LU1504937902.USD","LU1044875133.USD","LU2294711473.HKD","LU1718418525.SGD","LU2039709279.SGD","LU0348805143.USD","LU0572939691.SGD","LU1044874839.SGD","BK1531","LU0878004406.USD","LU0106959298.USD","LU0214875030.USD","LU1880383440.USD","LU0531970944.HKD","LU0396098781.USD","LU0672654166.SGD","LU2237443465.HKD","HK0001040143.USD","LU2125910849.SGD","LU1770034418.SGD","IE00B0169L03.USD","LU0140636845.USD","LU0210527791.USD","02196","LU0169518387.USD","LU0359201612.USD","LU1282649141.HKD","LU1303224171.USD","SG9999002828.SGD","LU0359201885.HKD","LU1211504680.USD","LU0588546209.SGD","HK0000352382.USD","LU0540923850.HKD","LU0269904917.USD","LU2237443978.SGD","LU2045819591.USD","LU0651947912.USD","LU1188198961.HKD","LU0469268626.HKD","IE0008368411.USD","BK1521","IE0032834883.USD","LU0348788117.USD","LU2462611646.USD","SG9999015952.SGD","LU1880383366.USD","LU0516422440.USD","LU0052750758.USD","SG9999002463.SGD","TSLA","LU1064131003.USD","LU1196710351.USD","LU0117841782.USD","LU0196878994.USD","TCHmain","LU0607220059.USD","HK0000306685.HKD","LU1282648689.USD","IE00B8HQ1Z84.USD","LU1961090484.USD","LU0345775950.USD","IE00B0169N27.USD","LU1328615791.USD","LU0821914370.USD","LU0231483743.USD","LU2362541273.HKD","LU0516422366.SGD","LU0307460666.USD","HK0000320223.HKD","LU1813983027.USD","LU1993786604.SGD","SG9999000418.SGD","SG9999015986.USD","LU0029875118.USD","META","LU0543330566.HKD","LU0516423174.USD","IE00B031HY20.USD","LU0175139822.USD","LU0164872284.USD","LU1226287529.USD","LU1808992512.USD","SGXZ81514606.USD","LU0918141887.USD","LU0348816934.USD","LU1046422090.SGD","LU0605514214.HKD","LU0132412106.USD","NVDA","LU0828237510.HKD","LU0164865239.USD","BK1615","LU1814569148.SGD","LU0259732245.USD","LU0886674414.USD","LU0106259558.USD","LU0320764599.SGD","LU1804176565.USD","IE00B3M56506.USD","LU0650527681.SGD","LU1048484197.HKD","LU0456842615.SGD","LU2023250504.SGD","LU0251144936.SGD","LU0348784397.USD","LU0675040207.SGD","LU2152927971.USD","LU0048580855.USD","LU0261950983.USD","LU0107464264.USD","LU0823426480.USD","IE00BQXX3D17.EUR","LU1439103000.SGD","LU2251237306.USD","LU0577902298.EUR","LU0261947096.USD","LU0708995583.HKD","LU0823038988.USD","LU1655091459.SGD","LU1568876251.USD","LU0348814723.USD","SG9999003461.SGD","LU1719994722.HKD","BK1096","LU0070217475.USD","LU0348723411.USD","LU2778985437.USD","LU1102505762.USD","LU0329678170.USD","LU0531971595.HKD","SG9999001093.SGD","LU0862451753.SGD","LU2148510915.USD","LU2362540622.SGD","LU1235295612.USD","BK1586","SG9999018865.SGD","LU1051769294.HKD","LU2133065610.SGD","LU0633140560.USD","LU0456827905.SGD","LU0608807946.USD","LU0203347892.USD","LU1439102457.SGD","TCEHY","LU2247934214.USD","LU0345769631.USD","LU0797268264.HKD","LU1196710195.USD","SG9999014880.SGD","LU0561508036.HKD","LU0254981946.USD","LU0315178854.USD","LU1917777945.USD","LU0737861699.HKD","LU0828238088.HKD","LU0499858602.USD","LU0634319403.HKD","LU2087589342.USD","LU0210526637.USD","LU0320764243.SGD","LU0516423091.SGD","LU0029874905.USD","SGXZ90724238.SGD","LU1196710864.SGD","SGXZ31699556.SGD","LU0449515922.USD","LU0287142896.SGD","LU0823039010.USD","LU2125910500.SGD","LU0417516738.SGD","LU0345776255.USD","LU0165289439.USD","LU2399975544.HKD","LU0463099449.HKD","LU1981816686.USD","LU2237443622.USD","LU0315179316.USD","LU0608807433.USD","LU0211977185.USD","LU0577902611.USD","LU0117844026.USD","LU0572940350.SGD","SG9999000459.SGD","IE0008368742.USD","LU2265009873.SGD","SG9999004220.SGD","LU1366334578.USD","LU1226288170.HKD","IE00B067MR52.USD","LU1720050803.USD","IE00B0JY6N72.USD","LU0348783662.USD","SGXZ99366536.SGD","LU1251922891.USD","LU2097828805.USD","LU0577902371.SGD","LU2317271919.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635780784","title":"Fosun Pharma's Unit's Registration Application for Blood Stasis Syndrome Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2635780784","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635780784?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:14","pubTimestamp":1778674455,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  unit Hebei Wanbang Folon Pharmaceutical's drug registration application for Tao Hong Si Wu Tang Granules was accepted by China's National Medical Products Administration.The drug is intended to be used for blood deficiency and blood stasis syndrome, according to a Wednesday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600196","BK0188","BK0060","02196","BK0096","BK0196","BK1191","BK1593","BK0175","BK0028","BK0187","BK1515","BK0239","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147733241","title":"FOSUN PHARMA's Application for Traditional Chinese Medicine New Drug Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1147733241","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147733241?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:35","pubTimestamp":1778672105,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0196","BK0028","600196","BK0096","BK0187","BK1515","BK0012","BK0060","BK0188","BK0239","BK1593","BK0175","02196","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789157","title":"Shanghai Fosun Pharma - Drug Registration Applications of Tao Hong Si Wu Tang Granules by Unit Accepted by Nmpa China","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789157?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:26","pubTimestamp":1778671618,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nFWN41Q13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0028","BK1515","BK0239","BK0188","BK0012","BK0060","BK1593","BK0183","BK0187","BK0196","BK0175","600196","02196","BK0096","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635891127","title":"Fosun Pharma unit Hebei Wanbang Fulin files NMPA registration for Taohong Siwu Tang granules","url":"https://stock-news.laohu8.com/highlight/detail?id=2635891127","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635891127?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:26","pubTimestamp":1778671610,"startTime":"0","endTime":"0","summary":"Hebei Wanbang Fulin Pharmaceutical, controlled unit of Shanghai Fosun Pharmaceutical, received National Medical Products Administration acceptance for drug registration filing for Taohong Siwu Tang granules.Product classified as Class 3.1 new traditional Chinese medicine; targets blood-deficiency and blood-stasis syndrome, including menstrual disorders.Cumulative R&D spending on program reached about CNY 6.96 million as of April 2026.Commercial launch remains subject to GMP compliance inspection, drug registration clearance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Ko","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL3XQXwv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0028","BK0239","BK0188","BK0196","BK1230","BK0183","600196","00656","BK0060","BK0012","BK0096","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635953789","title":"Fosun Pharma unit gains exclusive option on AriBio AR1001 Alzheimer’s rights outside China","url":"https://stock-news.laohu8.com/highlight/detail?id=2635953789","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635953789?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:23","pubTimestamp":1778671387,"startTime":"0","endTime":"0","summary":"Fosun Pharma-controlled Fosun Pharmaceutical Industry signed exclusive option agreement with South Korea-based AriBio on May 13 for AR1001, oral PDE-5 inhibitor in Phase III POLARIS-AD trial for early Alzheimer’s disease.Option allows Fosun Pharmaceutical Industry to decide within 90 days of receiving topline Phase III data whether to take exclusive rights to develop, register, manufacture, and commercialize AR1001 across global markets excluding China, Hong Kong, Macau, 10 Southeast Asian countries, and certain other territories.Agreement sets USD 60 million option fee, payable shortly after signing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL4V1W7q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00656","BK0012","BK0196","BK0239","BK0187","BK0175","BK0188","BK1230","BK0183","BK0028","BK0096","BK0060","600196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634068409","title":"Shanghai Fosun Pharma announces annual shareholder meeting notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2634068409","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634068409?lang=en_us&edition=fundamental","pubTime":"2026-05-11 16:46","pubTimestamp":1778489179,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical  will hold its annual general meeting in Shanghai on June 16, 2026.Shareholders will vote on 2025 annual report, board work report, profit distribution plan.Items also include reappointing Ernst & Young affiliates as 2026 onshore and offshore auditors, setting auditor remuneration for 2025.Mandates up for approval cover expanded entrusted loan and borrowing limits, additional credit facilities, disposal authority for listed equity holdings, issuance of interbank market debt financing instruments, expanded guarantee limits.Special resolutions include general mandates to issue up to 20% of A shares or H shares, repurchase up to 10% of H shares, repurchase up to 10% of A shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL7yWr8y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","BK0028","BK0175","BK0239","600196","BK0012","00656","BK1230","BK0196","BK0187","BK0060","BK0096","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634476272","title":"Fosun Pharma's Unit Gets Nod for Registration of Venlafaxine Hydrochloride Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2634476272","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634476272?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:45","pubTimestamp":1778471110,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical's  unit, Fosun Pharma , received approval from the National Medical Products Administration for the registration of venlafaxine hydrochloride extended-release tablets, according to a Shanghai bourse filing on Saturday.The pharmaceutical company's Shanghai shares rose less than 1% during Monday's morning trade.The drug is used to treat depression and generalized anxiety disorder.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0239","BK0060","BK0096","BK0175","BK0187","BK1191","02196","BK0028","600196","BK0188","BK0183","BK1593","BK1515","BK0196","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634475343","title":"Henlius Biotech Gets European Commission's Nod for Hetronifly","url":"https://stock-news.laohu8.com/highlight/detail?id=2634475343","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634475343?lang=en_us&edition=fundamental","pubTime":"2026-05-11 10:43","pubTimestamp":1778467398,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech (HKG:2696), Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) unit, received approval from the European Commission for its serplulimab injection, which has the trade name","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1191","HK0000320223.HKD","EPV","BK0187","BK4588","BK0183","BK0196","BK4585","HK0000320264.USD","HK0000165453.HKD","HK0000306701.USD","BK0060","02696","BK1593","BK1515","600196","BK0028","BK4581","XBI","BK0239","HK0000306685.HKD","02196","BK0175","BK1161","BK0188","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634442867","title":"Fosun unit Henlius wins FDA go-ahead for HLX05-N colorectal cancer trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2634442867","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634442867?lang=en_us&edition=fundamental","pubTime":"2026-05-10 18:15","pubTimestamp":1778408121,"startTime":"0","endTime":"0","summary":"Fosun Pharma-controlled Henlius won US FDA clearance to start a Phase 1 trial of HLX05-N for metastatic colorectal cancer in US.HLX05-N is a biosimilar version of cetuximab, being developed for metastatic colorectal cancer plus head and neck squamous cell carcinoma.R&D spending on HLX05-N reached about CNY 60 million as of April 2026.Global sales of cetuximab injection totaled about USD 1.66 billion in 2025, based on IQVIA MIDAS data cited in filing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 10, 2026, and is solely responsible for the info","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260510:nNDL8W1ZT4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306685.HKD","LU1201861165.SGD","HK0000320223.HKD","IQV","BK4588","BK0183","HK0000320264.USD","BK0012","BK0060","LU0528227936.USD","LU1201861249.SGD","BK0188","LU0648001328.SGD","LU1989764664.SGD","BK0239","LU1261432733.SGD","HK0000165453.HKD","00656","BK0196","BK0028","600196","BK4121","BK0187","LU1791710400.SGD","LU0130518102.USD","BK4530","LU0648000940.SGD","LU0477156797.USD","02696","LU0130103400.USD","LU0980610538.SGD","LU0477156953.USD","LU0130102774.USD","LU0882574055.USD","BK0096","BK1161","BK1230","LU1989764748.USD","LU1791710582.SGD","BK4585","BK0175","HK0000306701.USD","LU0198837287.USD","LU0130517989.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137889975","title":"FOSUN PHARMA's Biosimilar HLX05-N Receives FDA Clearance for US Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1137889975","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137889975?lang=en_us&edition=fundamental","pubTime":"2026-05-10 15:50","pubTimestamp":1778399419,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries (collectively referred to as \"Henlius\"), recently received approval from...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK0028","BK4588","600196","BK0096","BK0196","02196","BK1515","BK0060","BK0183","BK1593","BK0012","BK1191","BK4585","BK0187","BK0175","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105978375","title":"FOSUN PHARMA's Venlafaxine Hydrochloride Extended-Release Tablets Receive Market Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1105978375","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105978375?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:14","pubTimestamp":1778231677,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (02196) has announced that its controlled subsidiary, Fosun Pharma (Xuzhou) Co., Ltd., recently received approval from the National Medical Products Administration for the drug...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0096","BK0175","BK0183","BK0239","02196","BK1191","IPOS","BK0060","BK1515","BK0012","BK0188","BK0028","600196","BK0196","BK1593","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633443675","title":"Shanghai Fosun Pharma -  Drug Registration Application for Venlafaxine Hydrochloride Sustained-Release Tablets Approved by China's Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2633443675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633443675?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:11","pubTimestamp":1778231461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L0CE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK0239","BK1515","BK1593","BK0196","BK0187","600196","BK0028","02196","BK0188","BK0175","BK0060","BK0183","BK0012","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633436766","title":"Fosun Pharma unit wins China approval for venlafaxine sustained-release tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2633436766","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633436766?lang=en_us&edition=fundamental","pubTime":"2026-05-08 17:10","pubTimestamp":1778231436,"startTime":"0","endTime":"0","summary":"Shanghai Fosun Pharmaceutical received China NMPA registration clearance for venlafaxine hydrochloride sustained-release tablets, a 75 mg treatment for depression and generalized anxiety disorder.Fosun Pharma  holds marketing authorization and manufacturing rights for product.R&D spending reached RMB 7.68 million as of April 2026; 2025 China sales of venlafaxine preparations totaled about RMB 584 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 08, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL90VzXD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600196","BK0187","BK0096","BK0175","BK0183","BK0196","BK0188","BK0239","BK0028","00656","BK1230","BK0060","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633435663","title":"Sinopharm Group  Stock Sheds 1.6% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2633435663","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633435663?lang=en_us&edition=fundamental","pubTime":"2026-05-08 16:33","pubTimestamp":1778229180,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sinopharm Group Co. Ltd. shed 1.6% to 18.43 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 0.9% to 26393.71.The stock's fall snapped a two-day winning streak.Sinopharm Group Co. Ltd. closed 18% below its 52-week high of HK$22.34, which the company reached Feb. 25.The stock underperformed when compared to some of its competitors, as Shanghai Fosun Pharmaceutical  Co. Ltd. fell 0.2%.Trading volume totaled 6.2 million shares, compared to the 50-day average of 5.7 million shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","BK0096","BK0012","BK0060","BK1191","LU1115378108.SGD","BK4175","01099","BK0187","BK0188","BK0196","SHTDY","BK0028","02196","BK1500","BK0183","BK1197","600196","BK0239","BK1515","BK1593","LU0640798160.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","stockEarnings":[{"period":"1week","weight":-0.038},{"period":"1month","weight":-0.0715},{"period":"3month","weight":-0.096},{"period":"6month","weight":-0.1044},{"period":"1year","weight":0.0095},{"period":"ytd","weight":-0.0932}],"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","perCapita":"--","boardName":"医药制造业","registeredCapital":"267042万元","compareEarnings":[{"period":"1week","weight":-0.0189},{"period":"1month","weight":0.0196},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.0853},{"period":"1year","weight":0.2312},{"period":"ytd","weight":0.0487}],"survey":"　　上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。根据工信部中国医药工业信息中心颁布的“2024年度中国医药工业百强企业榜单”，本集团位列第5位。此外，在ESG方面，复星医药于报告期内荣登2025《财富》ESG影响力榜单，成为唯一入选该榜单的中国医药企业。根据MSCI于2025年7月公布的ESG年度评级结果，本集团MSCIESG评级提升至AA级。在AI领域，复星医药凭借自主研发的PharmAID医药智能平台荣获福布斯“2025中国人工智能科技创新场景应用企业TOP10”。","serverTime":1779353225794,"listedPrice":7.15,"stockholders":"0人","compareStock":{"symbol":"000001.SH","name":"SSE Comp"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.,600196,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票老虎国际,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票行情,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股价,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股市,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票价格,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票交易,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票购买,Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.(600196) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction